Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.


Betting on Biotech: Careers in Equity Research

Betting on Biotech

Presented By


Considering a career in the finance industry may seem odd in the midst of a global economic crisis. But it takes time to make the transition from bench scientist to equity research analyst, and the cyclical nature of the economy suggests that an upswing is inevitable if not imminent.

On February 5, 2009, Eric Staeva-Vieira, vice president and senior pharma and biotech analyst for Majestic Research, presented a webinar on careers in equity research for members of the Academy's Science Alliance. After offering some general career advice he explained that equity analysts provide investment advice to investment banks, hedge funds, or other investors, evaluating existing or future products from both scientific and financial perspectives. Staeva-Vieira then delved into the types of analyst jobs available to those with a science background, described the hard and soft skills required for the jobs, and discussed specific ways to prepare, such as taking finance courses.

Use the media tab above to view Staeva-Vieira's presentation.


Eric Staeva-Vieira, PhD

Majestic Research

Eric Staeva-Vieira is vice president and senior pharma & biotech analyst for Majestic Research, an independent equity research firm on Wall Street. Before joining Majestic, Eric previously worked as a biotech analyst on the traditional sell-side for Lazard Capital Markets and Rodman & Renshaw, both healthcare-oriented investment banks. Prior to his move on Wall Street, Eric was the program manager of the New York Academy of Sciences' Science Alliance. He received his PhD in developmental genetics from New York University in 2003.